Former ev3, Boston Scientific exec appointed as new Stentys CMO
Stentys, a next-generation drug-eluting bifurcation stent company, has appointed René Spaargaren, MD, as its chief medical officer (CMO).
Previously at ev3, Spaargaren was vice president of international clinical affairs since 2002, where he was responsible for driving new product development from research and development to acceptance by the medical community and launch into international markets, according to the Paris-based Stentys. Prior to ev3, Spaargaren served for seven years (1995-2002) with Boston Scientific as medical director in Europe; and for three years (1992-1995) as clinical manager in Europe with Medtronic.
Previously at ev3, Spaargaren was vice president of international clinical affairs since 2002, where he was responsible for driving new product development from research and development to acceptance by the medical community and launch into international markets, according to the Paris-based Stentys. Prior to ev3, Spaargaren served for seven years (1995-2002) with Boston Scientific as medical director in Europe; and for three years (1992-1995) as clinical manager in Europe with Medtronic.